Natera, Inc. announced that the American Journal of Transplantation (AJT) published findings from the PEDAL study, a significant multi-center trial. PEDAL is the first prospective study to evaluate longitudinal trends of donor-derived cell-free DNA (dd-cfDNA) to determine Prospera’s prognostic ability following kidney transplant rejection.
The study enrolled 488 kidney transplant recipients from 28 participating U.S. and international transplant centers over four years. Results demonstrated that Prospera dd-cfDNA trends post-rejection are strongly associated with and prognostic of one-year outcomes.
Key findings included that patients with persistently elevated dd-cfDNA had a 3.5 times higher risk of graft loss or death (p=0.0002), while patients who achieved dd-cfDNA clearance showed an impressive 97% one-year graft survival. This highlights Prospera’s critical role as a non-invasive tool for accurate risk stratification and personalized patient management post-rejection.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.